sobi
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
January 28, 2026Aspaveli, European Commission, Nephrology, sobi
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) for the treatment of two …
Mavatar announces research collaboration with Sobi
January 6, 2026Research and Development Immunology, Mavatar, Rare Diseases, sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …
FDA approves Gamifant for macrophage activation syndrome in Still’s disease
June 30, 2025Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …
Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
April 28, 2025Pharmacy sales & educational programmes, Sales and Marketing Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian …
EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment
June 19, 2024Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi
Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …
Sobi acquires CTI BioPharma Corporation for $1.7bn
May 10, 2023Medical Communications CTI, acquisition, sobi
Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …
FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis
November 21, 2018Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi
The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …
AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn
November 13, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi
AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …
Sobi receives expanded EU approval for Kineret
April 11, 2018Research and Development, Sales and Marketing Kineret, anti-inflammatory, biotech, drugs, pharma, pharmaceutical, sobi
Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval …
Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder
June 15, 2016Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi
Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …
Sobi, Biogen’s haemophilia B therapy gets European approval
May 13, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi
Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …
Sobi launches new haemophilia treatment in UK
January 19, 2016Manufacturing and Production, Sales and Marketing elocta, haemophilia a, sobi
Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU …
Sobi and Biogen’s haemophilia A treatment EU-approved
November 27, 2015Sales and Marketing Biogen, elocta, haemophilia a, sobi
Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …
EMA review for Biogen Idec’s haemophilia A therapy
November 4, 2014Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi
The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …
Latest content
FibroFind appoints Lee Borthwick as CEO
